JANX241115P25000
- 0.45
- 0.000.00%
Janux Therapeutics Newsroom
Janux Therapeutics Analyst Ratings
UBS Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $69
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Janux Therapeutics Analyst Ratings
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Stifel Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $70
Janux Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $63 Price Target
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)
BTIG Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $62
Buy Rating Affirmed on Janux Therapeutics Inc. Amidst Promising Prostate Cancer Program Developments and Unique Bispecific Platform
Janux Therapeutics Analyst Ratings
Scotiabank Maintains Sector Perform on Janux Therapeutics, Lowers Price Target to $42
Scotiabank Sticks to Its Hold Rating for Janux Therapeutics Inc (JANX)
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Wedbush Reiterates Outperform on Janux Therapeutics, Maintains $74 Price Target
Janux Therapeutics Analyst Ratings
TD Cowen Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
Janux Therapeutics (JANX.US) was first covered by Scotiabank, giving it the same rating as the market, with a target price of $47.00.